Advertisement covers IDWeek 2015


HIV Research Preview for IDWeek 2015

October 3, 2015

Here's a look at some of the noteworthy HIV research being presented at IDWeek 2015 in San Diego from Oct. 7 to 11. The conference features some of the latest science in and approaches to prevention, diagnosis, treatment and epidemiology of infectious diseases -- including HIV.

IDWeek 2015 is the fourth annual combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). Here's what to look forward to at the conference.

Antiretroviral Therapy: New Drugs and Treatment Outcomes

This session will feature updated study results on the single-tablet coformulation of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The data continues to support TAF as a better alternative to tenofovir (Viread). The U.S. Food and Drug Administration will decide on whether to approve the new coformulation of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild) containing TAF by early November 2015.

Additionally, another presentation will take a look at how the Affordable Care Act (ACA) has helped patients in Virginia enroll in care and achieve undetectable viral loads.


HIV Prevention, Early Diagnosis, STDs

This session not only will focus on prevention, but also will highlight early diagnosis and treatment for people living with HIV and sexually transmitted infections. One of the presentations examines how prescribing recommended HIV regimens versus non-recommended and other regimens affects likelihood of viral suppression and reported side effects. Another presentation will offer new data on the prevalence of gonorrhea and chlamydia in persons living with HIV.

HIV Complications and Co-Infections

This session will look at some of the complications and comorbidities that can arise for patients living with HIV. One presentation will highlight data on statins and their association with significantly lower incidence of liver disease progression in patients living with HIV and hepatitis C (HCV). We'll also see some new data on inflammation and racial disparities.

Warren Tong is the senior science editor for and

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2015 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO. It is a part of the publication IDWeek 2015.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.